Knoll Capital Management, LLC - Q2 2023 holdings

$82.5 Million is the total value of Knoll Capital Management, LLC's 27 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .

 Value Shares↓ Weighting
BHVN  Biohaven Pharmactl Hldg Co L$10,774,092
+75.1%
450,4220.0%13.06%
+37.7%
APLT  Applied Therapeutics Inc$4,416,000
+57.8%
3,450,0000.0%5.35%
+24.1%
VRNA  Verona Pharmasponsored ads$4,228,000
+5.3%
200,0000.0%5.12%
-17.2%
GDX  Vaneck Gold Miners ETFgold miners etf$2,765,603
-6.9%
91,8500.0%3.35%
-26.8%
SIL  Global X Silver Miners ETF 37954Y848global x silver$2,331,303
-15.4%
89,7000.0%2.83%
-33.5%
ENTX  Entera Bio Ltd$2,094,243
-27.3%
2,484,2750.0%2.54%
-42.8%
GDXJ  Vaneck Junior Gold Miners ETFjunior hold mine$1,895,329
-9.7%
53,1500.0%2.30%
-29.0%
BAH  Booz Allen Hamilton HLDG CORcl a$1,450,800
+20.4%
13,0000.0%1.76%
-5.3%
V  Visa$1,151,778
+5.3%
4,8500.0%1.40%
-17.2%
TMO  Thermo Fischer Scientific Inc$1,095,675
-9.7%
2,1000.0%1.33%
-29.0%
OCUL  Ocular Therapeutix Inc.$1,032,000
-31.4%
200,0000.0%1.25%
-46.0%
MO  Altria Group Inc$1,028,310
+1.5%
22,7000.0%1.25%
-20.1%
CVS  CVS Health Corp$1,002,385
-7.0%
14,5000.0%1.22%
-26.9%
FNV  Franco Nev Corp CAD$998,200
-2.2%
7,0000.0%1.21%
-23.1%
SILV  Silvercrest Metals Inc CAD$996,200
-4.5%
170,0000.0%1.21%
-24.9%
NOC  Northrop Grumman Corp$986,807
-1.3%
2,1650.0%1.20%
-22.4%
OR  OSISKO GOLD ROYALTIES LTD$969,200
-23.8%
400,0000.0%1.18%
-40.1%
 Omega Therapeutics Inc.$968,856
-7.1%
173,0100.0%1.18%
-26.9%
SA  SEABRIDGE GOLD INC$964,000
-6.9%
80,0000.0%1.17%
-26.8%
ORGS  Orgenesis, Inc.$882,285
+17.8%
634,7380.0%1.07%
-7.3%
OCUL  Ocular Therapeutix Inc.call$814,300
+61.3%
95,8000.0%0.99%
+26.9%
ALT  Altimmune Inc$613,739
-16.4%
173,8640.0%0.74%
-34.2%
OCUP  Ocuphire Pharma Inc.$434,000
+15.7%
100,0000.0%0.53%
-9.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-08-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Aldeyra Therapeutics Inc35Q3 202331.6%
Corbus Pharmaceuticals HLDGS30Q3 202246.5%
Abeona Therapeutics Inc30Q3 202234.8%
Biohaven Pharmactl Hldg Co L26Q3 202379.6%
Entera Bio Ltd22Q3 20237.8%
Ampio Pharmaceuticals Inc.21Q2 201811.0%
Soligenix Inc.20Q3 20221.7%
Eiger Biopharmaceuticals Inc19Q3 20225.8%
Applied Therapeutics Inc18Q3 202319.7%
Alcobra Ltd18Q3 20176.5%

View Knoll Capital Management, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Knoll Capital Management, LLC Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
HOOKIPA Pharma Inc.June 20, 20235,517,3856.8%
Applied Therapeutics Inc.January 23, 20233,450,0007.2%
Orgenesis Inc.August 14, 20201,316,3645.9%
Corbus Pharmaceuticals Holdings, Inc.February 14, 20205,045,8707.1%
ABEONA THERAPEUTICS INC.February 14, 20182,359,7675.0%
SOLIGENIX, INC.November 13, 2017870,0009.9%
ABEONA THERAPEUTICS INC.February 14, 20172,359,7675.9%
ALCOBRA LTD.February 14, 20171,205,4984.4%
Ampio Pharmaceuticals, Inc.February 14, 20172,738,3224.8%
RITTER PHARMACEUTICALS INCFebruary 14, 2017952,4348.2%

View Knoll Capital Management, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G/A2024-01-16
13F-HR2023-11-14
SC 13G2023-10-04
13F-HR2023-08-15
SC 13G2023-06-20
13F-HR2023-05-15
13F-HR2023-02-14
SC 13G2023-01-23

View Knoll Capital Management, LLC's complete filings history.

Compare quarters

Export Knoll Capital Management, LLC's holdings